Reardon et al. demonstrated that combinatorial therapy targeting CTLA-4 and PD-1 could cure 75% of mice, including those with advanced-stage tumours, and induce tumour-specific memory effects to overcome tumour recurrences. This evidence concerns the gene CTLA4 and neoplasm.